Doer Biologics Announces License Agreement with BioNTech
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – BNTX
The recorded move for BNTX in the trading session of this news was +0.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio's innovative discoveries to research, develop, manufacture, and commercialize innovative biotherapeutics against an undisclosed target. Doer Bio will receive an upfront payment and will be eligible for potential development, regulatory, and commercial milestone payments.
"This license agreement with BioNTech is a great demonstration of the enormous potential of Doer Bio's platform technologies, which has been well validated by extensive preclinical research and ongoing clinical studies," said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio.
"We are thrilled to work with BioNTech, a globally leading biopharmaceutical company, to translate our technologies and discoveries into novel therapies. We are looking forward to working with BioNTech to advance this innovation into clinic and ultimately benefit patients worldwide," commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio.
About Doer Bio
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers.
Doer Bio has developed multiple proprietary platform technologies, including xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Bio, please visit www.doerbio.com or contact bd@doerbio.com .
View original content to download multimedia:https://www.prnewswire.com/news-releases/doer-biologics-announces-license-agreement-with-biontech-301873714.html
SOURCE Zhejiang Doer Biologics Co., Ltd.